CMPSCOMPASS Pathways
$13.29
$0.00
(0.00%)
Overnight
EarningsJul 30
Mkt Cap$1.79B
Vol4.74M
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity New York, NY – June 30, 2026 – Market News Updates News Commentary – The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often […]
The post Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity appeared first on Financial News Media.
Financial News Media
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...
PR Newswire
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive...
Business Wire
Compass Pathways Elects Kathleen Tregoning to Board of Directors
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected...
Business Wire
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at...
Business Wire
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the...
Business Wire
Transcript: Compass Pathways Q1 2026 Earnings Conference Call
read more...
Benzinga
Compass Pathways Reports Strong Q1 Results, Shares Surge
COMPASS Pathways Plc (NASDAQ:CMPS) reported first-quarter earnings on Wednesday before the market open. Here's a rundown of the report.read more...
Benzinga
<
1
2
...
>
Advertisement|Remove ads.
Latest CMPS News
ViewMulti-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Financial News Media
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
PR Newswire
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression
Stocktwits
Advertisement|Remove ads.